0001193125-26-158122
SEC filingAlamar Biosciences is a commercial-stage proteomics company offering the ARGO HT System and NULISA technology for ultra-sensitive protein biomarker detection in blood, launched in January 2024 with rapid adoption evidenced by 196% Y/Y revenue growth to $74M in 2025. This IPO raises ~$133M to scale operations, expand manufacturing, and develop IVD products like ARGO HT/DX for FDA submission in 2027.
Alamar Biosciences has rapidly scaled since launching its ARGO HT proteomics platform in January 2024, achieving $74.2M revenue in 2025 (195% Y/Y growth) from $25.1M in 2024, driven by >100 instruments installed across >300 customers in 25 countries, including all top-10 biopharma firms. The razor-blade model shows promise with consumables at ~50% of 2025 revenue, average pull-through >$400K/instrument, and gross margins expanding to 56% via manufacturing efficiencies and pricing power. Losses narrowed to $29.8M amid $37M R&D spend, positioning for IVD expansion including ARGO HT/DX FDA submission in 2027 backed by $10M ADDF grant. Cash burn moderated but remains high at ~$54M annually; $30M cash + $56.5M Jan 2026 notes provide runway, with IPO proceeds funding sales/manufacturing scale-up.
The NULISA platform's moat lies in uniquely combining ultra-high attomolar sensitivity, proteoform specificity, 6,000-plex multiplexing, 12-log dynamic range, and full automation—validated in >100 publications (Nature, Cell) and collaborations (MJFF, DZNE, GNPC). Beachhead in neurology (CNS panels detecting BD-pTau217) expands to immunology/oncology; $4.1B advanced proteomics TAM could reach $20B by 2035. However, competition from Olink/Thermo Fisher and Quanterix looms, with ongoing Olink litigation alleging NULISA patent infringement (PTAB upheld patent; district court active).
Offering 9.375M shares (~14% dilution) at $16 midpoint yields $133M net (up to $154M greenshoe), post-money ~$1B valuation on 65M shares. Founders retain ~14% (Luo/Chen), VCs ~50% (Qiming 19%, Illumina 11%). No dividends planned; proceeds for ops/capex amid $10M SVB debt. EGC/smaller reporter status reduces disclosure burdens. Key risks: execution on diagnostics (FDA hurdles), supply chain (single antibody source), customer concentration (academia/biopharma), and burn sustainability. Strong insider alignment and tech validation support growth potential in $50B proteomics market.